Filing Flows

Filing Flows › Janux Therapeutics (JANX) › Next earnings date

Janux Therapeutics (JANX) earnings: beat the estimate

Janux Therapeutics (JANX) reported on Nov 5, 2026 and beat the EPS estimate: −$0.34 against −$0.49 (+30.4%). Revenue was $9.3M for Q3 2026, -7% year over year. It beat the EPS estimate in 80% of the quarters on record.

Last result+30.4% vs estimate
Beat rate80%

The last report

Janux Therapeutics reported revenue of $9.3M for the third quarter 2026 (-7% Y/Y), net loss $21.6M. How it makes money → · Every quarter →

Janux Therapeutics: EPS against the estimate, last 5 reportsJanux Therapeutics: EPS against the estimate, last 5 reportsEstimateReported−$0.61−$0.39Nov 25−$0.64−$0.51Feb 26−$0.52−$0.39May 26−$0.29−$0.35Aug 26−$0.49−$0.34Nov 26
Latest (Nov 26): Estimate −$0.49, Reported −$0.34.
JANX: the stock's move on each reportJANX: the stock's move on each reportAug 6, 2026-0.9%May 7, 2026-3.0%Feb 26, 2026-0.7%Nov 6, 2025-3.8%

Janux Therapeutics' latest quarter

Janux Therapeutics, Q3 2026: revenue $9.3M (-7% year over year), operating margin -336.5%, net loss $21.6M, operating cash flow −$25.2M. The chart follows the revenue to costs, profit and cash.

Questions

Did Janux Therapeutics beat earnings?

Janux Therapeutics (JANX) reported on Nov 5, 2026 and beat the EPS estimate: −$0.34 against −$0.49 (+30.4%).

When does JANX report earnings?

The next date is not set yet.

Does Janux Therapeutics usually beat earnings?

It beat the consensus EPS estimate in 80% of the quarters on record.

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.